바이러스 불활성화 시장 : 제품, 방법, 용도, 최종사용자별 - 세계 예측(2025-2030년)

The Viral Inactivation Market was valued at USD 977.41 million in 2023, expected to reach USD 1,119.48 million in 2024, and is projected to grow at a CAGR of 14.62%, to USD 2,541.74 million by 2030.

Viral inactivation is a critical process in biopharmaceutical manufacturing and healthcare, designed to neutralize potential viral contaminants in biologics, vaccines, and blood products. This process is essential for ensuring the safety and efficacy of pharmaceutical products, thereby protecting public health. Moreover, its application spans various fields, including pharmaceuticals, biotechnology, blood transfusion, and diagnostic laboratories, with end-use sectors comprising hospitals, diagnostic centers, and research institutions. The market is primarily driven by increasing regulatory standards for biologic safety and the rising demand for effective and safe therapeutics. Growth is further propelled by advancements in technologies such as solvent/detergent treatment, pasteurization, low pH treatment, and UV irradiation, enabling reliable viral inactivation. Additionally, the escalating prevalence of chronic diseases and increased focus on personalized medicine have expanded the potential for viral inactivation applications. However, challenges such as high operational costs, technical complexities, and stringent regulatory compliance may hamper market growth. The market faces geographical limitations due to varying regulations and infrastructure disparities, particularly in developing economies. Opportunities lie in adopting innovative technologies and developing multimodal inactivation platforms, which can broaden applicability and enhance process efficiency. Research into more efficient, cost-effective methods, and technologies that can handle newer and more resistant viral strains are imperative for driving growth. Companies should prioritize strategic partnerships and investment in R&D to harness these opportunities effectively. Despite the promising nature of the market, the intricate regulatory landscape and the possible adverse effects on product quality due to process-induced alterations remain significant hurdles. Overall, staying ahead through innovation and adapting to evolving regulatory standards while ensuring cost-effectiveness are key strategies for businesses aiming to thrive in the viral inactivation market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Viral Inactivation Market

The Viral Inactivation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in the global prevalence of chronic diseases
  • Growing government support for pharmaceutical & biotechnology industries
  • Rising number of new drug approvals
• Market Restraints
  • High costs associated with the manufacture of biosimilar products
• Market Opportunities
  • Technological integrations in viral inactivation procedures
  • Strong R&D investments in the life sciences industry
• Market Challenges
  • Strict government regulatory guidelines

Porter's Five Forces: A Strategic Tool for Navigating the Viral Inactivation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Viral Inactivation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Viral Inactivation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Viral Inactivation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Viral Inactivation Market

A detailed market share analysis in the Viral Inactivation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Viral Inactivation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Viral Inactivation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Viral Inactivation Market

A strategic analysis of the Viral Inactivation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Viral Inactivation Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Charles River Laboratories International, Inc., Cytiva by Danaher Corporation, Eurofins Scientific (Ireland) Limited, HiMedia Laboratories, LLC, Lonza Group Ltd., Merck KGaA, Parker Hannifin Corporation, PromoCell GmbH, Rad Source Technologies, Inc., Sartorius AG, Thermo Fisher Scientific Inc, and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Viral Inactivation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Kits & Reagents, Services, and Viral Inactivation Systems & Accessories.
• Based on Method, market is studied across Pasteurization and Solvent Detergent Method.
• Based on Application, market is studied across Blood & Blood Product, Cellular & Gene Therapy Product, Stem Cell Product, Tissues & Tissue Product, and Vaccines & Therapeutic.
• Based on End User, market is studied across Academic Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the global prevalence of chronic diseases
    • 5.1.1.2. Growing government support for pharmaceutical & biotechnology industries
    • 5.1.1.3. Rising number of new drug approvals
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with the manufacture of biosimilar products
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological integrations in viral inactivation procedures
    • 5.1.3.2. Strong R&D investments in the life sciences industry
  • 5.1.4. Challenges
    • 5.1.4.1. Strict government regulatory guidelines
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Viral Inactivation Market, by Product

• 6.1. Introduction
• 6.2. Kits & Reagents
• 6.3. Services
• 6.4. Viral Inactivation Systems & Accessories

7. Viral Inactivation Market, by Method

• 7.1. Introduction
• 7.2. Pasteurization
• 7.3. Solvent Detergent Method

8. Viral Inactivation Market, by Application

• 8.1. Introduction
• 8.2. Blood & Blood Product
• 8.3. Cellular & Gene Therapy Product
• 8.4. Stem Cell Product
• 8.5. Tissues & Tissue Product
• 8.6. Vaccines & Therapeutic

9. Viral Inactivation Market, by End User

• 9.1. Introduction
• 9.2. Academic Research Institutes
• 9.3. Contract Research Organizations
• 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Viral Inactivation Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Viral Inactivation Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Viral Inactivation Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agilent Technologies, Inc.
• 2. Becton, Dickinson and Company
• 3. Bio-Rad Laboratories, Inc.
• 4. Charles River Laboratories International, Inc.
• 5. Cytiva by Danaher Corporation
• 6. Eurofins Scientific (Ireland) Limited
• 7. HiMedia Laboratories, LLC
• 8. Lonza Group Ltd.
• 9. Merck KGaA
• 10. Parker Hannifin Corporation
• 11. PromoCell GmbH
• 12. Rad Source Technologies, Inc.
• 13. Sartorius AG
• 14. Thermo Fisher Scientific Inc
• 15. WuXi AppTec Co., Ltd.